Key facts
- Sylke’s last known valuation is $160.0M (Jul 2025).
- It has raised $15.5M; the latest was Early Stage VC ($10.0M) in Jul 2025.
- Notable investors include ASPS Innovation & Entrepreneurship Hub, Vaark Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sylke
- ·The full record, as it builds
Funding rounds
No funding rounds for Sylke are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sylke
Operator of an advanced wound closure solutions company intended to address common challenges in post-surgical healing. The company offers a solution to the problems with its innovative design made from a proprietary silk fibroin, which provides a breathable, water-resistant, and biocompatible alternative to conventional adhesives, with a focus on patient comfort, enabling clients to enhance the healing process across all surgical specialties
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2022
- Employees
- 23
- Website
- sylke.com/
- Ownership
- Privately Held (backing)
Sylke doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sylke shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sylke in its N-PORT filings yet. We sweep new filings monthly.